三星医疗(601567) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥3,107,668,549.87, a decrease of 9.56% compared to the same period last year[3] - Total profit for the quarter was ¥378,801,775.05, down 50.10% year-over-year[3] - Net profit attributable to shareholders was ¥298,100,911.93, reflecting a decline of 55.22% compared to the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥143,825,308.45, a significant drop of 78.54% year-over-year[3] - The basic earnings per share for the quarter was ¥0.21, down 55.03% from the same period last year[3] - Net profit for the first three quarters of 2025 was CNY 1,506,796,242.67, a decrease of 17.3% from CNY 1,822,779,409.65 in 2024[20] - Earnings per share (EPS) for the first three quarters of 2025 was CNY 1.08, down from CNY 1.29 in the same period of 2024[22] - The company reported a total comprehensive income of ¥431,586,311.37 for the first three quarters of 2025, down from ¥539,637,737.89 in the same period of 2024[30] Cash Flow - The net cash flow from operating activities was ¥517,267,564.70, a decrease of 32.73% compared to the previous year[3] - In the first three quarters of 2025, the net cash flow from operating activities was ¥458,011,287.76, a decrease of 55.5% compared to ¥1,029,211,957.25 in the same period of 2024[24] - Total cash inflow from operating activities for the first three quarters of 2025 was ¥10,404,489,143.43, up 6.3% from ¥9,788,478,776.79 in 2024[24] - The cash outflow from operating activities increased to ¥9,946,477,855.67 in 2025, compared to ¥8,759,266,819.54 in 2024, reflecting a rise of 13.5%[24] - The company experienced a net cash outflow from financing activities of ¥1,721,170,096.41 in the first three quarters of 2025, compared to a net outflow of ¥2,710,951,807.47 in the same period of 2024[33] Assets and Liabilities - Total assets at the end of the quarter were ¥24,156,894,322.04, a decrease of 1.31% from the end of the previous year[4] - The total assets as of September 30, 2025, reached ¥14,321,788,079.64, an increase of 10.1% from ¥12,932,806,743.68 at the end of 2024[26] - The company's total liabilities increased to ¥6,536,169,593.84 in 2025, compared to ¥4,390,923,329.33 in 2024, marking a rise of 48.9%[27] - The total liabilities decreased from CNY 12,202,548,432.10 in the previous year to CNY 11,490,388,612.32, a reduction of approximately 5.8%[16] - The total equity decreased to ¥6,785,618,485.80 in 2025 from ¥6,541,883,000.00 in 2024, indicating a decline of 3.7%[27] - The total equity increased from CNY 12,273,938,154.83 to CNY 12,666,505,709.71, reflecting a growth of about 3.2%[16] Orders and Production - Total orders on hand reached RMB 17.914 billion, a year-on-year increase of 14.69%[13] - Overseas distribution orders on hand amounted to RMB 2.169 billion, growing by 125.45% year-on-year[13] - The company plans to establish a new production base in Kenya by July 2025 to support business expansion in Africa[13] Research and Development - Research and development expenses for the first three quarters were CNY 421,981,091.96, slightly up from CNY 413,019,007.29 in the previous year[19] - Research and development expenses for the first three quarters of 2025 were ¥96,734,878.23, a decrease of 4.9% compared to ¥101,240,517.46 in the first three quarters of 2024[29] Other Financial Metrics - The weighted average return on equity was 2.45%, a decrease of 12.47% from the end of the previous year[4] - Non-recurring gains and losses for the quarter totaled ¥154,275,603.48, down from ¥248,293,933.48 in the previous year[6] - Financial expenses showed a significant improvement, with a net income of CNY -108,671,097.00 compared to CNY 77,987,744.96 in the previous year[19] - The company reported an investment income of CNY 178,574,515.32, which is a slight increase from CNY 177,637,485.16 in the same period last year[20] - Other comprehensive income after tax for the first three quarters of 2025 was -¥57,086,153.27, compared to -¥7,714,780.00 in the same period of 2024[30]